Differences in Cardiovascular Risk Prediction Scoring in Individuals with Autoimmune Rheumatic Diseases
Individuals with autoimmune rheumatic diseases (ARD) have a higher risk of cardiovascular disease than the general population. However, the classic 10-year cardiovascular risk scoring systems have not adequately incorporated this heightened risk into the prediction equations. The growing number of peer-reviewed articles in the professional literature is an indication of how individuals in the scholastic arena are expanding in the awareness of the link between ARDs and cardiovascular disease (CVD). By dissemination of best practices, other health care practitioners can learn about the specific needs of this specific subgroup of patients with ARD. The purpose of the literature review conducted here was to describe the status of the peer-reviewed literature pertaining to ARD versus CVD and raise awareness about what variables need to be included to adequately include the ARD subgroup. A literature search was conducted using the CINAHL, Medline, and PubMed databases. Inclusion criteria included publication date from January 1, 1995 through July 31, 2015, written in the English language, and a focus on cardiovascular disease as the primary discipline. Cardiovascular risk score was searched as an overarching discipline; articles focused on sub-disciplines or other health professions disciplines were excluded. The search resulted in 265 articles. Each of the authors reviewed the abstracts for all articles and read full articles when necessary. The result was 13 articles that were then considered in depth. The articles were categorized according to their primary theme: risk scoring method (N=6); link between ARD and CVD (N=3); physician knowledge about ARD and CVD link (N=2); limitations of scoring system (N=2). Year of publication and journal were also examined. The results of the literature search lead to several observations about how the peer-reviewed literature has been used to date and how it could be used to create more robust scoring methods on predicting CVD.
Rheumatoid Arthritis, Cardiovascular Disease, Systemic Lupus Erythematosus, Autoimmune
[1]
Isenberg, D., Manzi, S., & Hughes, G. R. V. (2008). Lupus. Oxford: Oxford University Press.
[2]
Alarcón-Riquelme, M. E., Ziegler, J. T., Molineros, J., Howard, T. D., Moreno-Estrada, A., Sánchez-Rodríguez, E., … Jacob, C. O. (2015). GWAS in an Amerindian ancestry population reveals novel systemic lupus erythematosus risk loci and the role of European admixture. Arthritis & Rheumatology (Hoboken, N.J.). http://doi.org/10.1002/art.39504.
[3]
Holl-Ulrich, K., & Rose, C. (2015). [Non-infectious granulomatous inflammation : Focus on the lungs and skin]. Der Pathologe. http://doi.org/10.1007/s00292-015-0119-7.
[4]
Iguchi-Hashimoto, M., Hashimoto, M., Fujii, T., Hamaguchi, M., Furu, M., Ishikawa, M., … Mimori, T. (2015). The association between serious infection and disease outcome in patients with rheumatoid arthritis. Clinical Rheumatology. http://doi.org/10.1007/s10067-015-3143-3.
[5]
Infantino, M., Meacci, F., Grossi, V., Benucci, M., Morozzi, G., Tonutti, E., … Bizzaro, N. (2015). Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. Arthritis Research & Therapy, 17, 365. http://doi.org/10.1186/s13075-015-0871-3
[6]
Soto, M. E., Hernández-Becerril, N., Perez-Chiney, A. C., Hernández-Rizo, A., Telich-Tarriba, J. E., Juárez-Orozco, L. E., … Bojalil, R. (2015). Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: Analytical study in a specialized health institute, one year follow-up. Results in Immunology, 5, 13–22. http://doi.org/10.1016/j.rinim.2013.10.003
[7]
Sudoł-Szopińska, I., Kwiatkowska, B., Prochorec-Sobieszek, M., & Maśliński, W. (2015). Enthesopathies and enthesitis. Part 1. Etiopathogenesis. Journal of Ultrasonography, 15(60), 72–84. http://doi.org/10.15557/JoU.2015.0006.
[8]
Thanassoulis, G., Lyass, A., Benjamin, E., Larson, M., Vita, J., Levy, D., & Vasan, R. (2012). Relations of exercise blood pressure response to cardiovascular risk factors and vascular function in the framingham heart study. Circulation, 125(23), 2836-2843.
[9]
Sacre, K., Escoubet, B., Zennaro, M.-C., Chauveheid, M.-P., Gayat, E., & Papo, T. (2015). Overweight Is a Major Contributor to Atherosclerosis in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Cross-Sectional Controlled Study. Medicine, 94(48), e2177. http://doi.org/10.1097/MD.0000000000002177
[10]
Moya, F. B., Pineda Galindo, L. F., & García de la Peña, M. (2016). Impact of Chronic Glucocorticoid Treatment on Cardiovascular Risk Profile in Patients with Systemic Lupus Erythematosus. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 22(1), 8–12. http://doi.org/10.1097/RHU.0000000000000335
[11]
Lee, M.-S., Flammer, A. J., Li, J., Lennon, R. J., Delacroix, S., Kim, H., & Lerman, A. (2015). Comparison of Time Trends of Cardiovascular Disease Risk Factors and Framingham Risk Score Between Patients With and Without Acute Coronary Syndrome Undergoing Percutaneous Intervention Over the Last 17 Years: From the Mayo Clinic Percutaneous Coronary Intervention Registry. Clinical Cardiology. http://doi.org/10.1002/clc.22484.
[12]
Kawada, T. (2015). Framingham risk score of metabolically unhealthy obese individuals defined by insulin resistance and metabolic components. Nutrition (Burbank, Los Angeles County, Calif.). http://doi.org/10.1016/j.nut.2015.10.007.
[13]
Mathieu, R., Powell-Wiley, T., Ayers, C., McGuire, D., Khera, A., Das, S., & Lakoski, S. (2012). Physical activity participation, health perceptions, and cardiovascular disease mortality in a multiethnic population: The Dallas Heart Study. American Heart Journal, 163(6), 1037-1040.
[14]
Bansal, D., Nayakallu, R. S. R., Gudala, K., Vyamasuni, R., & Bhansali, A. (2015). Agreement between Framingham Risk Score and United Kingdom Prospective Diabetes Study Risk Engine in Identifying High Coronary Heart Disease Risk in North Indian Population. Diabetes & Metabolism Journal, 39(4), 321–327. http://doi.org/10.4093/dmj.2015.39.4.321.
[15]
Kawai, V., Solus, J., Oeser, A., Rho, Y., Raggi, P., Bian, A., & Stein, C. (2011). Novel cardiovascular risk prediction models in patients with systemic lupus erythematosus. Lupus, 20(14), 1526-1534.
[16]
Bengtsson, C., Ohman, M., Nived, O., & Rantapää Dahlqvist, S. (2012). Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus, 21(4), 452-459.
[17]
Bell, C., & Rowe, I. F. (2011). The Recognition and Assessment of Cardiovascular Risk in People with Rheumatoid Arthritis in Primary Care: A Questionnaire-Based Study of General Practitioners. Musculoskeletal Care, 9(2), 69-74. doi:10.1002/msc.196.
[18]
Cugno, M., Ingegnoli, F., Gualtierotti, R., & Fantini, F. (2010). Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Current Vascular Pharmacology, 8(2), 285-292.
[19]
Sayin, M. R., Cetiner, M. A., Karabag, T., Akpinar, I., Sayin, E., Kurcer, M. A., … Aydin, M. (2014). Framingham risk score and severity of coronary artery disease. Herz, 39(5), 638–643. http://doi.org/10.1007/s00059-013-3881-4.
[20]
Móczár, C. (2013). [Comparison of SCORE and Reynolds cardiovascular risk assessments in a cohort without cardiovascular disease]. Orvosi Hetilap, 154(43), 1709–1712. http://doi.org/10.1556/OH.2013.29730.
[21]
Van Staa, T.-P., Gulliford, M., Ng, E. S.-W., Goldacre, B., & Smeeth, L. (2014). Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk? Plos One, 9(10), e106455–e106455. http://doi.org/10.1371/journal.pone.0106455.
[22]
Loprinzi, P. D., & Davis, R. E. (2015). Daily Movement Patterns and Predicted 10-yr Risk for a First Atherosclerotic Cardiovascular Disease (ASCVD) Event Using the Pooled Cohort Risk Equations among US Adults. Preventive Medicine. http://doi.org/10.1016/j.ypmed.2015.08.008.
[23]
Deanfield, J. (2014). JBS3 guideline focuses on both short-term and lifetime risk of CVD. Guidelines in Practice, 17(8), 11–15.
